BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 21, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/18 cls
Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) Bloom Burton Philippa Flint Upgrade Hold (from sell) -13% $1.18
Dundee David Martin Upgrade Buy (from neutral)
Flint upgraded after Aeterna raised $12.1M in a registered direct offering. She estimates the company now has sufficient cash through early 4Q11, before anticipated Phase III data for perifosine to treat colorectal cancer and multiple myeloma (MM) in November and December, respectively. Flint thinks the stock may increase as Phase III data approaches, so there is a "reasonable chance" that warrants from...

Read the full 695 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >